PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsprecursor cell lymphoblastic leukemia-lymphoma
MeSH D054198 - precursor cell lymphoblastic leukemia-lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D007945:Lymphoid leukemia
46 Companies
14 Drugs
$
Success rate
D054198: 
Precursor cell lymphoblastic leukemia-lymphoma
47 Companies
20 Drugs
$
Success rate
D015452:Precursor b-cell lymphoblastic leukemia-lymphoma
1 Company
1 Drug
$
Success rate
D054218:Precursor t-cell lymphoblastic leukemia-lymphoma
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDaunorubicin Daunorubicin  1998-06-23   
Doxorubicin Doxorubicin  1995-07-28   
Idarubicin Idarubicin  2002-05-01   
Ifosfamide, Mesna Ifosfamide/mesna  2002-02-26   
Imatinib Imatinib Teva  2013-01-07   
Doxorubicin Myocet (previously Myocet)  2000-07-13   
Cyclophosphamide Neosar  1993-04-29   
IngenusCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
MylanDoxorubicin Doxorubicin  2011-10-28   
Ifosfamide Ifosfamide  2012-11-26   
Mercaptopurine Mercaptopurine  2005-07-01   
Rising PharmaceuticalsIdarubicin Idarubicin  2012-10-11   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
SandozIdarubicin Idarubicin  2011-03-29   
Cyclophosphamide Cyclophosphamide  2023-09-12   
NovartisImatinib Glivec  2001-11-07   
SanofiDaunorubicin Cerubidine  1982-01-01   
Clofarabine Evoltra  2006-05-29   
WyethInotuzumab ozogamicin Besponsa  2017-08-17   
Daunorubicin Cerubidine  1982-01-01   
PfizerDoxorubicin Adriamycin  1991-01-30   
Inotuzumab ozogamicin Besponsa  2017-06-28 $236 M Y2023 
Doxorubicin Doxorubicin  1982-01-01   
Idarubicin Idamycin  1990-09-27   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
65%
139/215
Phase 2
42%
83/199
Phase 3
59%
69/117
Approved: 21Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Cyclophosphamide,
Doxorubicin,
Doxorubicin hydrochloride,
Idarubicin,
Imatinib,
Imatinib mesylate
Mylan
Mercaptopurine
Novartis
Imatinib,
Imatinib mesylate,
Tbo-filgrastim,
Cilmostim,
Lenograstim,
Calcium dobesilate,
Regramostim,
Sodium lactate,
Microcrystalline cellulose
Sanofi
Clofarabine,
Daunorubicin,
Daunorubicin hydrochloride,
Mycophenolate sodium,
Tbo-filgrastim,
Lenograstim,
COLTUXIMAB RAVTANSINE
Pfizer
Inotuzumab ozogamicin,
Doxorubicin,
Doxorubicin hydrochloride,
Idarubicin,
Salicylic acid,
Antithrombin iii,
Cilmostim,
Calcium dobesilate,
Terfenadine,
Serine,
Sodium lactate,
Microcrystalline cellulose
Dr Reddys Laboratories
Doxorubicin,
Doxorubicin hydrochloride
1
2
3
4
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use